Medicinal Attributes of Heterocyclic Compounds in Rheumatoid Arthritis: Recent Developments and SAR Studies

American College of Rheumatology. Availabe from: https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis (Accessed on 06 August 2020).

Singh, S.; Singh, T.G.; Mahajan, K.; Dhiman, S. Medicinal plants used against various inflammatory biomarkers for the management of rheumatoid arthritis. J. Pharm. Pharmacol., 2020, 72(10), 1306-1327.
[http://dx.doi.org/10.1111/jphp.13326] [PMID: 32812250]

Hu, X.X.; Wu, Y.J.; Zhang, J.; Wei, W. T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis. Int. Immunopharmacol., 2019, 70, 428-434.
[http://dx.doi.org/10.1016/j.intimp.2019.03.008] [PMID: 30856393]

Choy, E.H.; Panayi, G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med., 2001, 344(12), 907-916.
[http://dx.doi.org/10.1056/NEJM200103223441207] [PMID: 11259725]

Mateen, S.; Zafar, A.; Moin, S.; Khan, A.Q.; Zubair, S. Understanding the role of cytokines in the pathogenesis of rheumatoid arthritis. Clin. Chim. Acta, 2016, 455, 161-171.
[http://dx.doi.org/10.1016/j.cca.2016.02.010] [PMID: 26883280]

Nimesh, S. Herbal drug is better than allopathic drug in the treatment of rheumatoid arthritis. Indian J. Pharmacol., 2018, 5, 539-545.
[http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.5(9).539-45]

Moelants, E.A.; Mortier, A.; Van Damme, J.; Proost, P. Regulation of TNF-α with a focus on rheumatoid arthritis. Immunol. Cell Biol., 2013, 91(6), 393-401.
[http://dx.doi.org/10.1038/icb.2013.15] [PMID: 23628802]

Jeong, J.W.; Lee, H.H.; Lee, K.W.; Kim, K.Y.; Kim, S.G.; Hong, S.H.; Kim, G.Y.; Park, C.; Kim, H.K.; Choi, Y.W.; Choi, Y.H. Mori folium inhibits interleukin-1β-induced expression of matrix metalloproteinases and inflammatory mediators by suppressing the activation of NF-κB and p38 MAPK in SW1353 human chondrocytes. Int. J. Mol., 2016, 37(2), 452-460.
[http://dx.doi.org/10.3892/ijmm.2015.2443] [PMID: 26707272]

van der Linden, M.P.; van der Woude, D.; Ioan-Facsinay, A.; Levarht, E.W.; Stoeken-Rijsbergen, G.; Huizinga, T.W.; Toes, R.E.; van der Helm-van Mil, A.H. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis. Arthritis Rheum., 2009, 60(8), 2232-2241.
[http://dx.doi.org/10.1002/art.24716] [PMID: 19644872]

Farzaei, M.H.; Farzaei, F.; Abdollahi, M.; Abbasabadi, Z.; Abdolghaffari, A.H.; Mehraban, B. A mechanistic review on medicinal plants used for rheumatoid arthritis in traditional Persian medicine. J. Pharm. Pharmacol., 2016, 68(10), 1233-1248.
[http://dx.doi.org/10.1111/jphp.12606] [PMID: 27417522]

Asif Amin, M.; Fox, D.A.; Ruth, J.H. Synovial cellular and molecular markers in rheumatoid arthritis. Semin. Immunopathol., 2017, 39(4), 385-393.
[http://dx.doi.org/10.1007/s00281-017-0631-3] [PMID: 28497350]

Singh, J.A.; Saag, K.G.; Bridges, S.L., Jr; Akl, E.A.; Bannuru, R.R.; Sullivan, M.C.; Vaysbrot, E.; McNaughton, C.; Osani, M.; Shmerling, R.H.; Curtis, J.R.; Furst, D.E.; Parks, D.; Kavanaugh, A.; O’Dell, J.; King, C.; Leong, A.; Matteson, E.L.; Schousboe, J.T.; Drevlow, B.; Ginsberg, S.; Grober, J.; St Clair, E.W.; Tindall, E.; Miller, A.S.; McAlindon, T. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol., 2016, 68(1), 1-26.
[http://dx.doi.org/10.1002/art.39480] [PMID: 26545940]

Agca, R.; Heslinga, S.C.; Rollefstad, S.; Heslinga, M.; McInnes, I.B.; Peters, M.J.; Kvien, T.K.; Dougados, M.; Radner, H.; Atzeni, F.; Primdahl, J.; Södergren, A.; Wallberg Jonsson, S.; van Rompay, J.; Zabalan, C.; Pedersen, T.R.; Jacobsson, L.; de Vlam, K.; Gonzalez-Gay, M.A.; Semb, A.G.; Kitas, G.D.; Smulders, Y.M.; Szekanecz, Z.; Sattar, N.; Symmons, D.P.; Nurmohamed, M.T. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis., 2017, 76(1), 17-28.
[http://dx.doi.org/10.1136/annrheumdis-2016-209775] [PMID: 27697765]

Pesu, M.; Candotti, F.; Husa, M.; Hofmann, S.R.; Notarangelo, L.D.; O’Shea, J.J. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol. Rev., 2005, 203(1), 127-142.
[http://dx.doi.org/10.1111/j.0105-2896.2005.00220.x] [PMID: 15661026]

Changelian, P.S.; Flanagan, M.E.; Ball, D.J.; Kent, C.R.; Magnuson, K.S.; Martin, W.H.; Rizzuti, B.J.; Sawyer, P.S.; Perry, B.D.; Brissette, W.H.; McCurdy, S.P.; Kudlacz, E.M.; Conklyn, M.J.; Elliott, E.A.; Koslov, E.R.; Fisher, M.B.; Strelevitz, T.J.; Yoon, K.; Whipple, D.A.; Sun, J.; Munchhof, M.J.; Doty, J.L.; Casavant, J.M.; Blumenkopf, T.A.; Hines, M.; Brown, M.F.; Lillie, B.M.; Subramanyam, C.; Shang-Poa, C.; Milici, A.J.; Beckius, G.E.; Moyer, J.D.; Su, C.; Woodworth, T.G.; Gaweco, A.S.; Beals, C.R.; Littman, B.H.; Fisher, D.A.; Smith, J.F.; Zagouras, P.; Magna, H.A.; Saltarelli, M.J.; Johnson, K.S.; Nelms, L.F.; Des Etages, S.G.; Hayes, L.S.; Kawabata, T.T.; Finco-Kent, D.; Baker, D.L.; Larson, M.; Si, M.S.; Paniagua, R.; Higgins, J.; Holm, B.; Reitz, B.; Zhou, Y.J.; Morris, R.E.; O’Shea, J.J.; Borie, D.C. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science, 2003, 302(5646), 875-878.
[http://dx.doi.org/10.1126/science.1087061] [PMID: 14593182]

Dowty, M.E.; Jesson, M.I.; Ghosh, S.; Lee, J.; Meyer, D.M.; Krishnaswami, S.; Kishore, N. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J. Pharmacol. Exp. Ther., 2014, 348(1), 165-173.
[http://dx.doi.org/10.1124/jpet.113.209304] [PMID: 24218541]

Fleischmann, R.; Mysler, E.; Hall, S.; Kivitz, A.J.; Moots, R.J.; Luo, Z.; DeMasi, R.; Soma, K.; Zhang, R.; Takiya, L.; Tatulych, S.; Mojcik, C.; Krishnaswami, S.; Menon, S.; Smolen, J.S.; Adams, L.; Ally, M.M.; du Plooy, M.C.; Louw, I.C.; Nayiager, S. Nel, C.B.; Nel, D.; Reuter, H.; Soloman, A.S.; Spargo, C.E.; Hall, S.; Rischmueller, M.; Sharma, S.D.; Will, R.K.; Youssef, P.P.; Arroyo, C.; Baes, R.P.; Dulos, R.B.; Hao, L.T.; Lanzon, A.E.; Lichauco, J.J.T.; Mangubat, J.H.; Ramiterre, E.B.; Reyes, B.H.M.; Tan, P.P.; Choe, J-Y.; Kang, Y.M.; Kwon, S.R.; Lee, S-H.; Lee, S-S.; Yoo, D-H.; Lin, H-Y.; Luo, S-F.; Tsai, S-T.; Tsai, W-C.; Tseng, J-C.; Wei, C-C.C.; Asavatanabodee, P.; Nantiruj, K.; Nilganuwong, S.; Uea-Areewongsa, P.; Majstorovic, L.B.; Bacic, S.M.; Batalov, A.Z.; Georgieva-Slavcheva, G.; Mihailova, M.; Nikolov, N.G.; Penev, D.P.; Spasov, Y.A.; Stanimirova, K.; Todorov, S.; Toncheva, A.R.; Yordanova, N.; Mosterova, Z.; Novosad, L.; Prochazkova, L.; Stehlikova, H.; Stejfova, Z.; Kiseleva, N.; Pank, L.; Savi, T.; Alexandra, B-G.; Amital, H.; Mevorach, D.; Rosner, I.A.; Mihailova, A.; Stumbra-Stumberga, E.; Basijokiene, V.; Lietuvininkiene, V.; Unikiene, D.; Brzezicki, J.; Dudek, A.M.; Glowacka-Kulesz, M.B.; Grabowicz-Wasko, B.; Hajduk-Kubacka, S.; Hilt, J.; Hrycaj, P.; Jeka, S.; Kolasa, R.; Krogulec, M.; Mastalerz, H.; Olak-Popko, A.; Owczarek, E.; Ruzga, Z.; Walczak, A.; Ancuta, C.I.; Ancuta, I.; Balanescu, A.R.; Berghea, F.; Bojin, S.; Arvunescu, M.A.I.; Ionescu, R.M.; Mociran, E.; Pavel, M.; Rednic, S.; Voie, A.; Zainea, C.M.; Bugrova, O.V.; Demin, A.; Ershova, O.B.; Gavrisheva, I.A.; Krechikova, D.G.; Kuropatkin, G.V.; Marusenko, I.M.; Menshikova, I.V.; Noskov, S.M.; Rebrov, A.P.; Smakotina, S.A.; Yakushin, S.S.; Zhilyaev, E.; Ramos, J.J.A.; Garcia, F.J.B.; Nebro, A.F.; Esteban, S.P.; Burson, J.M.S.; Sala, R.S.; Ataman, S.; Hizmetli, S.; Kuru, O.; Douglas, K.M.; Emery, P.; Moots, R.J.; Ong, V.H.; Sheeran, T.P.; Faraawi, R.Y.; Lessard, C.; Mendoza, C.A.; Avila-Armengol, H.E.; Zapata, F.I.A.; Irazoque-Palazuelos, F.C.; Cecena, M.A.M.; Pacheco-Tena, C.F.; Rizo-Rodriguez, J.C.; Rodriguez-Torres, I.M.; Aelion, J.A.; Caciolo, B.A.; Calmes, J.M.; Chatpar, P.; Dayal, N.; De Jesus, A.; Dikranian, A.H.; Diri, E.; Fairfax, M.J.; Fenton, I.F.; Fleischmann, R.M.; Gaylis, N.B.; George, R.L.; Halter, D.G.; Hernandez, P.; Hole, S.A.; Hou, A.C.; Huff, J.P.; Kafaja, S.; Kennedy, A.C.; Kenney, H.; Kimmel, S.C.; Kirby, B.S.; Kivitz, A.J.; Legerton, C.W.; Lindsey, S.M.; Mallepalli, J.R.; Mathews, S.D.; Metyas, S.K.; Mizutani, W.T.; Najam, S.; Nascimento, J.M.; Pang, S.W.; Patel, R.C.; Poiley, J.E.; Ramirez, C.E.; Reddy, R.; Rehman, Q.; Schnitz, W.M.; Scoville, C.D.; Shergy, W.J.; Silverfield, J.C.; Singhal, A.K.; Smallwood-Sherrer, Y.R.; Songcharoen, S.N.; Stack, M.T.; Stohl, W.; Su, T-I.K.; Udell, J.; Waraich, S.; Weidmann, C.E.; Wei, N.; Wiesenhutter, C.W.; Winkler, A.E.; Zagar, K.E.; Berman, A.; Mysler, E.F.; Hidalgo, R.A.P.; Venarotti, H.O.; Sariego, I.A.G.; Calabresse, R.E.J.; Ruiz-Tagle, J.I.V.; Vargas, L.F.M.B.; Berrocal, A.E.; Portocarrero, M.G.L.; Jesus, F.; Pena, R. ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet, 2017, 390(10093), 457-468.
[http://dx.doi.org/10.1016/S0140-6736(17)31618-5] [PMID: 28629665]

Tanaka, Y.; Sugiyama, N.; Toyoizumi, S.; Lukic, T.; Lamba, M.; Zhang, R.; Chen, C.; Stock, T.; Valdez, H.; Mojcik, C.; Fan, H.; Deng, C.; Yuasa, H. Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: A randomized, phase III, non-inferiority study. Rheumatology (Oxford), 2019, 58(1), 70-79.
[http://dx.doi.org/10.1093/rheumatology/key250] [PMID: 30137547]

Jiang, J.K.; Ghoreschi, K.; Deflorian, F.; Chen, Z.; Perreira, M.; Pesu, M.; Smith, J.; Nguyen, D.T.; Liu, E.H.; Leister, W.; Costanzi, S.; O’Shea, J.J.; Thomas, C.J. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J. Med. Chem., 2008, 51(24), 8012-8018.
[http://dx.doi.org/10.1021/jm801142b] [PMID: 19053756]

Combe, B.; Kivitz, A.; Tanaka, Y.; van der Heijde, D.; Simon, J.A.; Baraf, H.S.B.; Kumar, U.; Matzkies, F.; Bartok, B.; Ye, L.; Guo, Y.; Tasset, C.; Sundy, J.S.; Jahreis, A.; Genovese, M.C.; Mozaffarian, N.; Landewé, R.B.M.; Bae, S.C.; Keystone, E.C.; Nash, P. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: A phase III randomised clinical trial. Ann. Rheum. Dis., 2021, 80(7), 848-858.
[http://dx.doi.org/10.1136/annrheumdis-2020-219214] [PMID: 33504485]

Van Rompaey, L.; Galien, R.; van der Aar, E.M.; Clement-Lacroix, P.; Nelles, L.; Smets, B.; Lepescheux, L.; Christophe, T.; Conrath, K.; Vandeghinste, N.; Vayssiere, B.; De Vos, S.; Fletcher, S.; Brys, R.; van ’t Klooster, G.; Feyen, J.H.; Menet, C. Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J. Immunol., 2013, 191(7), 3568-3577.
[http://dx.doi.org/10.4049/jimmunol.1201348] [PMID: 24006460]

Fridman, J.S.; Scherle, P.A.; Collins, R.; Burn, T.C.; Li, Y.; Li, J.; Covington, M.B.; Thomas, B.; Collier, P.; Favata, M.F.; Wen, X.; Shi, J.; McGee, R.; Haley, P.J.; Shepard, S.; Rodgers, J.D.; Yeleswaram, S.; Hollis, G.; Newton, R.C.; Metcalf, B.; Friedman, S.M.; Vaddi, K. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: Preclinical characterization of INCB028050. J. Immunol., 2010, 184(9), 5298-5307.
[http://dx.doi.org/10.4049/jimmunol.0902819] [PMID: 20363976]

van Vollenhoven, R.F. Small molecular compounds in development for rheumatoid arthritis. Curr. Opin. Rheumatol., 2013, 25(3), 391-397.
[http://dx.doi.org/10.1097/BOR.0b013e32835fd828] [PMID: 23492738]

Yang, Y.; Li, X.F.; Zhang, X.; Bao, C.D.; Hu, J.K.; Xu, J.H.; Li, X.P.; Xu, J.; He, D.Y.; Li, Z.J.; Wang, G.C.; Wu, H.J.; Ji, F.; Zhan, L.J.; Zerbini, C.A.F.; Li, Z.G. Efficacy and safety of baricitinib in chinese rheumatoid arthritis patients and the subgroup analyses: Results from study RA-balancE. Rheumatol. Ther., 2020, 7(4), 851-866.
[http://dx.doi.org/10.1007/s40744-020-00231-6] [PMID: 32876903]

Yamaoka, K.; Tanaka, Y.; Kameda, H.; Khan, N.; Sasaki, N.; Harigai, M.; Song, Y.; Zhang, Y.; Takeuchi, T. The safety profile of upadacitinib in patients with rheumatoid arthritis in Japan. Drug Saf., 2021, 44(6), 711-722.
[http://dx.doi.org/10.1007/s40264-021-01067-x] [PMID: 34041702]

Tanaka, Y.; Takeuchi, T.; Tanaka, S.; Kawakami, A.; Iwasaki, M.; Song, Y.W.; Chen, Y.H.; Wei, J.C.; Lee, S.H.; Rokuda, M.; Izutsu, H.; Ushijima, S.; Kaneko, Y.; Akazawa, R.; Shiomi, T.; Yamada, E. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: A randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann. Rheum. Dis., 2019, 78(10), 1320-1332.
[http://dx.doi.org/10.1136/annrheumdis-2019-215163] [PMID: 31350270]

Baker, K.F.; Isaacs, J.D. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann. Rheum. Dis., 2018, 77(2), 175-187.
[http://dx.doi.org/10.1136/annrheumdis-2017-211555] [PMID: 28765121]

Lindvall, J.M.; Blomberg, K.E.; Väliaho, J.; Vargas, L.; Heinonen, J.E.; Berglöf, A.; Mohamed, A.J.; Nore, B.F.; Vihinen, M.; Smith, C.I. Bruton’s tyrosine kinase: Cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling. Immunol. Rev., 2005, 203(1), 200-215.
[http://dx.doi.org/10.1111/j.0105-2896.2005.00225.x] [PMID: 15661031]

Kelly, V.; Genovese, M. Novel small molecule therapeutics in rheumatoid arthritis. Rheumatology (Oxford), 2013, 52(7), 1155-1162.
[http://dx.doi.org/10.1093/rheumatology/kes367] [PMID: 23297340]

Di Paolo, J.A.; Huang, T.; Balazs, M.; Barbosa, J.; Barck, K.H.; Bravo, B.J.; Carano, R.A.; Darrow, J.; Davies, D.R.; DeForge, L.E.; Diehl, L.; Ferrando, R.; Gallion, S.L.; Giannetti, A.M.; Gribling, P.; Hurez, V.; Hymowitz, S.G.; Jones, R.; Kropf, J.E.; Lee, W.P.; Maciejewski, P.M.; Mitchell, S.A.; Rong, H.; Staker, B.L.; Whitney, J.A.; Yeh, S.; Young, W.B.; Yu, C.; Zhang, J.; Reif, K.; Currie, K.S. Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat. Chem. Biol., 2011, 7(1), 41-50.
[http://dx.doi.org/10.1038/nchembio.481] [PMID: 21113169]

Norman, P. Investigational Bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. Expert Opin. Investig. Drugs, 2016, 25(8), 891-899.
[http://dx.doi.org/10.1080/13543784.2016.1182499] [PMID: 27148767]

Schafer, P.H.; Kivitz, A.J.; Ma, J.; Korish, S.; Sutherland, D.; Li, L.; Azaryan, A.; Kosek, J.; Adams, M.; Capone, L.; Hur, E.M.; Hough, D.R.; Ringheim, G.E. Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: Results from a mechanistic study. Rheumatol. Ther., 2020, 7(1), 101-119.
[http://dx.doi.org/10.1007/s40744-019-00182-7] [PMID: 31721017]

Bonilla-Hernán, M.G.; Miranda-Carús, M.E.; Martin-Mola, E. New drugs beyond biologics in rheumatoid arthritis: The kinase inhibitors. Rheumatology (Oxford), 2011, 50(9), 1542-1550.
[http://dx.doi.org/10.1093/rheumatology/ker192] [PMID: 21622522]

Sweeney, S.E.; Firestein, G.S. Primer: Signal transduction in rheumatic disease--a clinician’s guide. Nat. Clin. Pract. Rheumatol., 2007, 3(11), 651-660.
[http://dx.doi.org/10.1038/ncprheum0631] [PMID: 17968336]

Singh, V.J.; Sharma, B.; Chawla, P.A. Recent developments in mitogen activated protein kinase inhibitors as potential anticancer agents. Bioorg. Chem., 2021, 114, 105161.
[http://dx.doi.org/10.1016/j.bioorg.2021.105161] [PMID: 34328852]

Zhang, Y.L.; Dong, C. MAP kinases in immune responses. Cell. Mol. Immunol., 2005, 2(1), 20-27.
[PMID: 16212907]

Riccaboni, M.; Bianchi, I.; Petrillo, P. Spleen tyrosine kinases: Biology, therapeutic targets and drugs. Drug Discov. Today, 2010, 15(13-14), 517-530.
[http://dx.doi.org/10.1016/j.drudis.2010.05.001] [PMID: 20553955]

Pamuk, O.N.; Tsokos, G.C. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res. Ther., 2010, 12(6), 222.
[http://dx.doi.org/10.1186/ar3198] [PMID: 21211067]

Tohyama, Y.; Yamamura, H. Protein tyrosine kinase, syk: A key player in phagocytic cells. J. Biochem., 2009, 145(3), 267-273.
[http://dx.doi.org/10.1093/jb/mvp001] [PMID: 19124456]

Mócsai, A.; Ruland, J.; Tybulewicz, V.L. The SYK tyrosine kinase: A crucial player in diverse biological functions. Nat. Rev. Immunol., 2010, 10(6), 387-402.
[http://dx.doi.org/10.1038/nri2765] [PMID: 20467426]

Diaz-Meco, M.T.; Moscat, J. The atypical PKCs in inflammation: NF-κB and beyond. Immunol. Rev., 2012, 246(1), 154-167.
[http://dx.doi.org/10.1111/j.1600-065X.2012.01093.x] [PMID: 22435553]

Hirai, T.; Chida, K. Protein kinase Czeta (PKCzeta): Activation mechanisms and cellular functions. J. Biochem., 2003, 133(1), 1-7.
[http://dx.doi.org/10.1093/jb/mvg017] [PMID: 12761192]

Liu, Z.; Sun, H.X.; Zhang, Y.W.; Li, Y.F.; Zuo, J.; Meng, Y.; Fang, F.D. Effect of SNPs in protein kinase C zeta gene on gene expression in the reporter gene detection system. World J. Gastroenterol., 2004, 10(16), 2357-2360.
[http://dx.doi.org/10.3748/wjg.v10.i16.2357] [PMID: 15285019]

Chang, X.; Han, J.; Zhao, Y.; Yan, X.; Sun, S.; Cui, Y. Increased expression of carbonic anhydrase I in the synovium of patients with ankylosing spondylitis. BMC Musculoskelet. Disord., 2010, 11(1), 279.
[http://dx.doi.org/10.1186/1471-2474-11-279] [PMID: 21143847]

Zheng, Y.; Wang, L.; Zhang, W.; Xu, H.; Chang, X. Transgenic mice over-expressing carbonic anhydrase I showed aggravated joint inflammation and tissue destruction. BMC Musculoskelet. Disord., 2012, 13(1), 256.
[http://dx.doi.org/10.1186/1471-2474-13-256] [PMID: 23256642]

Deutsch, O.; Krief, G.; Konttinen, Y.T.; Zaks, B.; Wong, D.T.; Aframian, D.J.; Palmon, A. Identification of Sjögren’s syndrome oral fluid biomarker candidates following high-abundance protein depletion. Rheumatology (Oxford), 2015, 54(5), 884-890.
[http://dx.doi.org/10.1093/rheumatology/keu405] [PMID: 25339641]

Liu, C.; Wei, Y.; Wang, J.; Pi, L.; Huang, J.; Wang, P. Carbonic anhydrases III and IV autoantibodies in rheumatoid arthritis, systemic lupus erythematosus, diabetes, hypertensive renal disease, and heart failure. Clin. Dev. Immunol., 2012, 2012, 354594.
[http://dx.doi.org/10.1155/2012/354594] [PMID: 23049597]

Fensome, A.; Ambler, C.M.; Arnold, E.; Banker, M.E.; Brown, M.F.; Chrencik, J.; Clark, J.D.; Dowty, M.E.; Efremov, I.V.; Flick, A.; Gerstenberger, B.S.; Gopalsamy, A.; Hayward, M.M.; Hegen, M.; Hollingshead, B.D.; Jussif, J.; Knafels, J.D.; Limburg, D.C.; Lin, D.; Lin, T.H.; Pierce, B.S.; Saiah, E.; Sharma, R.; Symanowicz, P.T.; Telliez, J.B.; Trujillo, J.I.; Vajdos, F.F.; Vincent, F.; Wan, Z.K.; Xing, L.; Yang, X.; Yang, X.; Zhang, L. Dual inhibition of tyk2 and jak1 for the treatment of autoimmune diseases: Discovery of ((s)-2,2-difluorocyclopropyl)((1 r,5 s)-3-(2-((1-methyl-1 h-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo] [3.2.1]octan-8-yl)methanone (PF-06700841). J. Med. Chem., 2018, 61(19), 8597-8612.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00917] [PMID: 30113844]

Caldwell, R.D.; Qiu, H.; Askew, B.C.; Bender, A.T.; Brugger, N.; Camps, M.; Dhanabal, M.; Dutt, V.; Eichhorn, T.; Gardberg, A.S.; Goutopoulos, A.; Grenningloh, R.; Head, J.; Healey, B.; Hodous, B.L.; Huck, B.R.; Johnson, T.L.; Jones, C.; Jones, R.C.; Mochalkin, I.; Morandi, F.; Nguyen, N.; Meyring, M.; Potnick, J.R.; Santos, D.C.; Schmidt, R.; Sherer, B.; Shutes, A.; Urbahns, K.; Follis, A.V.; Wegener, A.A.; Zimmerli, S.C.; Liu-Bujalski, L. Discovery of evobrutinib: An oral, potent, and highly selective, covalent bruton’s tyrosine kinase (BTK) Inhibitor for the treatment of immunological diseases. J. Med. Chem., 2019, 62(17), 7643-7655.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00794] [PMID: 31368705]

Huang, Z.; Zhang, Q.; Yan, L.; Zhong, G.; Zhang, L.; Tan, X.; Wang, Y. Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton’s tyrosine kinase for treatment of Rheumatoid arthritis. Bioorg. Med. Chem. Lett., 2016, 26(8), 1954-1957.
[http://dx.doi.org/10.1016/j.bmcl.2016.03.011] [PMID: 26976214]

Li, X.; Huang, Y.; Cheng, J.; Zhang, L.; Mao, F.; Zhu, J.; Sheng, C.; Li, J. Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis. Bioorg. Med. Chem., 2018, 26(15), 4375-4381.
[http://dx.doi.org/10.1016/j.bmc.2018.06.029] [PMID: 30078608]

Zhang, C.; Pei, H.; He, J.; Zhu, J.; Li, W.; Niu, T.; Xiang, M.; Chen, L. Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton’s tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis. Eur. J. Med. Chem., 2019, 169, 121-143.
[http://dx.doi.org/10.1016/j.ejmech.2019.02.077] [PMID: 30875504]

He, L.; Pei, H.; Zhang, C.; Shao, M.; Li, D.; Tang, M.; Wang, T.; Chen, X.; Xiang, M.; Chen, L. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis. Eur. J. Med. Chem., 2018, 145, 96-112.
[http://dx.doi.org/10.1016/j.ejmech.2017.12.079] [PMID: 29324347]

Vazquez, M.L.; Kaila, N.; Strohbach, J.W.; Trzupek, J.D.; Brown, M.F.; Flanagan, M.E.; Mitton-Fry, M.J.; Johnson, T.A.; TenBrink, R.E.; Arnold, E.P.; Basak, A.; Heasley, S.E.; Kwon, S.; Langille, J.; Parikh, M.D.; Griffin, S.H.; Casavant, J.M.; Duclos, B.A.; Fenwick, A.E.; Harris, T.M.; Han, S.; Caspers, N.; Dowty, M.E.; Yang, X.; Banker, M.E.; Hegen, M.; Symanowicz, P.T.; Li, L.; Wang, L.; Lin, T.H.; Jussif, J.; Clark, J.D.; Telliez, J.B.; Robinson, R.P.; Unwalla, R. Identification of N-cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutylpropane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases. J. Med. Chem., 2018, 61(3), 1130-1152.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01598] [PMID: 29298069]

Pei, H.; He, L.; Shao, M.; Yang, Z.; Ran, Y.; Li, D.; Zhou, Y.; Tang, M.; Wang, T.; Gong, Y.; Chen, X.; Yang, S.; Xiang, M.; Chen, L. Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. Sci. Rep., 2018, 8(1), 5273.
[http://dx.doi.org/10.1038/s41598-018-23569-y] [PMID: 29588471]

Keretsu, S.; Bhujbal, S.P.; Cho, S.J. Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations. J. Biomol. Struct. Dyn., 2021, 39(3), 753-765.
[http://dx.doi.org/10.1080/07391102.2020.1714483] [PMID: 31916502]

Thakkar, M.; Bhuniya, D.; Kaduskar, R.; Mengawade, T.; Naik, K.; Salunkhe, V.; Bhalerao, A.; Kurhade, S.; Mavinahalli, J.; Jain, V.; Petla, R.; Avaragolla, S.; Ray, S.; Rouduri, S.; Dhanave, A.; De, S.; Pathade, V.; Tambe, A.; Raje, A.A.; Madgula, V.; Joshi, S.; Nadeem, A.; Bala, M.; Umrani, D.; Hariharan, N.; Kulkarni, B.; Mookhtiar, K.A. Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis. Bioorg. Med. Chem. Lett., 2017, 27(8), 1867-1873.
[http://dx.doi.org/10.1016/j.bmcl.2017.02.026] [PMID: 28279528]

Yin, Y.; Chen, C.J.; Yu, R.N.; Shu, L.; Wang, Z.J.; Zhang, T.T.; Zhang, D.Y. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis. Bioorg. Chem., 2020, 98, 103720.
[http://dx.doi.org/10.1016/j.bioorg.2020.103720] [PMID: 32171982]

Shi, J.B.; Chen, L.Z.; Wang, B.S.; Huang, X.; Jiao, M.M.; Liu, M.M.; Tang, W.J.; Liu, X.H. Novel pyrazolo [4, 3-d] pyrimidine as potent and orally active inducible nitric oxide synthase (iNOS) dimerization inhibitor with efficacy in rheumatoid arthritis mouse model. J. Med. Chem., 2019, 62(8), 4013-4031.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00039] [PMID: 30925056]

Albrecht, W.; Unger, A.; Bauer, S.M.; Laufer, S.A. Discovery of N-{4-[5-(4-Fluorophenyl)-3-methyl-2-methylsulfanyl-3 H-imida-zol-4-yl]-pyridin-2-yl}-acetamide (CBS-3595), a Dual p38α MAPK/PDE-4 Inhibitor with Activity against TNFα-Related Diseases. J. Med. Chem., 2017, 60, 5290-5305.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01647] [PMID: 28613871]

Crawford, J.J.; Johnson, A.R.; Misner, D.L.; Belmont, L.D.; Castanedo, G.; Choy, R.; Coraggio, M.; Dong, L.; Eigenbrot, C.; Erickson, R.; Ghilardi, N.; Hau, J.; Katewa, A.; Kohli, P.B.; Lee, W.; Lubach, J.W.; McKenzie, B.S.; Ortwine, D.F.; Schutt, L.; Tay, S.; Wei, B.; Reif, K.; Liu, L.; Wong, H.; Young, W.B. Discovery of GDC-0853: A potent, selective, and noncovalent bruton’s tyrosine kinase inhibitor in early clinical development. J. Med. Chem., 2018, 61(6), 2227-2245.
[http://dx.doi.org/10.1021/acs.jmedchem.7b01712] [PMID: 29457982]

Zhang, X.; Sheng, X.; Shen, J.; Zhang, S.; Sun, W.; Shen, C.; Li, Y.; Wang, J.; Lv, H.; Cui, M.; Zhu, Y.; Huang, L.; Hao, D.; Qi, Z.; Sun, G.; Mao, W.; Pan, Y.; Shen, L.; Li, X.; Hu, G.; Gong, Z.; Han, S.; Li, J.; Chen, S.; Tu, R.; Wang, X.; Wu, C. Discovery and evaluation of pyrazolo[3,4-d]pyridazinone as a potent and orally active irreversible BTK inhibitor. ACS Med. Chem. Lett., 2019, 11(10), 1863-1868.
[http://dx.doi.org/10.1021/acsmedchemlett.9b00395] [PMID: 33062165]

Liu, J.; Guiadeen, D.; Krikorian, A.; Gao, X.; Wang, J.; Babu Boga, S. Alhassan, A.B.; Yu, W.; Selyutin, O.; Yu, Y.; Anand, R.; Xu, J.; Kelly, J.; Duffy, J.L.; Liu, S.; Yang, C.; Wu, H.; Cai, J.; Bennett, C.; Maloney, K.M.; Tyagarajan, S.; Gao, Y.D.; Fischmann, T.O.; Presland, J.; Mansueto, M.; Xu, Z.; Leccese, E.; Zhang-Hoover, J.; Knemeyer, I.; Garlisi, C.G.; Stivers, P.; Brandish, P.E.; Hicks, A.; Kim, R.; Kozlowski, J.A. Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes. Bioorg. Med. Chem. Lett., 2020, 30(17), 127390.
[http://dx.doi.org/10.1016/j.bmcl.2020.127390] [PMID: 32738973]

Liu, J.; Guiadeen, D.; Krikorian, A.; Gao, X.; Wang, J.; Boga, S.B.; Alhassan, A.B.; Yu, Y.; Vaccaro, H.; Liu, S.; Yang, C.; Wu, H.; Cooper, A.; de Man, J.; Kaptein, A.; Maloney, K.; Hornak, V.; Gao, Y.D.; Fischmann, T.O.; Raaijmakers, H.; Vu-Pham, D.; Presland, J.; Mansueto, M.; Xu, Z.; Leccese, E.; Zhang-Hoover, J.; Knemeyer, I.; Garlisi, C.G.; Bays, N.; Stivers, P.; Brandish, P.E.; Hicks, A.; Kim, R.; Kozlowski, J.A. Discovery of 8-amino-imidazo[1,5-a]pyrazines as reversible btk inhibitors for the treatment of rheumatoid arthritis. ACS Med. Chem. Lett., 2015, 7(2), 198-203.
[http://dx.doi.org/10.1021/acsmedchemlett.5b00463] [PMID: 26985298]

Qiu, H.; Ali, Z.; Bender, A.; Caldwell, R.; Chen, Y.Y.; Fang, Z.; Gardberg, A.; Glaser, N.; Goettsche, A.; Goutopoulos, A.; Grenningloh, R.; Hanschke, B.; Head, J.; Johnson, T.; Jones, C.; Jones, R.; Kulkarni, S.; Maurer, C.; Morandi, F.; Neagu, C.; Poetzsch, S.; Potnick, J.; Schmidt, R.; Roe, K.; Viacava Follis, A.; Wing, C.; Zhu, X.; Sherer, B. Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. Bioorg. Med. Chem., 2021, 40, 116163.
[http://dx.doi.org/10.1016/j.bmc.2021.116163] [PMID: 33932711]

Wang, X.; Barbosa, J.; Blomgren, P.; Bremer, M.C.; Chen, J.; Crawford, J.J.; Deng, W.; Dong, L.; Eigenbrot, C.; Gallion, S.; Hau, J.; Hu, H.; Johnson, A.R.; Katewa, A.; Kropf, J.E.; Lee, S.H.; Liu, L.; Lubach, J.W.; Macaluso, J.; Maciejewski, P.; Mitchell, S.A.; Ortwine, D.F.; DiPaolo, J.; Reif, K.; Scheerens, H.; Schmitt, A.; Wong, H.; Xiong, J.M.; Xu, J.; Zhao, Z.; Zhou, F.; Currie, K.S.; Young, W.B. Discovery of potent and selective tricyclic inhibitors of bruton’s tyrosine kinase with improved druglike properties. ACS Med. Chem. Lett., 2017, 8(6), 608-613.
[http://dx.doi.org/10.1021/acsmedchemlett.7b00103] [PMID: 28626519]

Elsayed, M.S.A.; Nielsen, J.J.; Park, S.; Park, J.; Liu, Q.; Kim, C.H.; Pommier, Y.; Agama, K.; Low, P.S.; Cushman, M. Application of sequential palladium catalysis for the discovery of janus kinase inhibitors in the benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) series. J. Med. Chem., 2018, 61(23), 10440-10462.
[http://dx.doi.org/10.1021/acs.jmedchem.8b00510] [PMID: 30460842]

Chough, C.; Joung, M.; Lee, S.; Lee, J.; Kim, J.H.; Kim, B.M. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor. Bioorg. Med. Chem., 2018, 26(8), 1495-1510.
[http://dx.doi.org/10.1016/j.bmc.2018.01.021] [PMID: 29452839]

Kawahata, W.; Asami, T.; Kiyoi, T.; Irie, T.; Taniguchi, H.; Asamitsu, Y.; Inoue, T.; Miyake, T.; Sawa, M. Design and synthesis of novel amino-triazine analogues as selective Bruton’s tyrosine kinase inhibitors for treatment of rheumatoid arthritis. J. Med. Chem., 2018, 61(19), 8917-8933.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01147] [PMID: 30216722]

Watterson, S.H.; De Lucca, G.V.; Shi, Q.; Langevine, C.M.; Liu, Q.; Batt, D.G.; Beaudoin Bertrand, M.; Gong, H.; Dai, J.; Yip, S.; Li, P.; Sun, D.; Wu, D.R.; Wang, C.; Zhang, Y.; Traeger, S.C.; Pattoli, M.A.; Skala, S.; Cheng, L.; Obermeier, M.T.; Vickery, R.; Discenza, L.N.; D’Arienzo, C.J.; Zhang, Y.; Heimrich, E.; Gillooly, K.M.; Taylor, T.L.; Pulicicchio, C.; McIntyre, K.W.; Galella, M.A.; Tebben, A.J.; Muckelbauer, J.K.; Chang, C.; Rampulla, R.; Mathur, A.; Salter-Cid, L.; Barrish, J.C.; Carter, P.H.; Fura, A.; Burke, J.R.; Tino, J.A. Discovery of 6-fluoro-5-(r)-(3-(s)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A reversible inhibitor of bruton’s tyrosine kinase (btk) conformationally constrained by two locked atropisomers. J. Med. Chem., 2016, 59(19), 9173-9200.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01088] [PMID: 27583770]

He, L.; Pei, H.; Lan, T.; Tang, M.; Zhang, C.; Chen, L. Design and synthesis of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis. Arch. Pharm. (Weinheim), 2017, 350(11), 1700194.
[http://dx.doi.org/10.1002/ardp.201700194] [PMID: 28944566]

Yao, X.; Sun, X.; Jin, S.; Yang, L.; Xu, H.; Rao, Y. Discovery of 4-aminoquinoline-3-carboxamide derivatives as potent reversible bruton’s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis. J. Med. Chem., 2019, 62(14), 6561-6574.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00329] [PMID: 31260299]

Wu, H.; Huang, Q.; Qi, Z.; Chen, Y.; Wang, A.; Chen, C.; Liang, Q.; Wang, J.; Chen, W.; Dong, J.; Yu, K.; Hu, C.; Wang, W.; Liu, X.; Deng, Y.; Wang, L.; Wang, B.; Li, X.; Gray, N.S.; Liu, J.; Wei, W.; Liu, Q. Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model. Sci. Rep., 2017, 7(1), 466.
[http://dx.doi.org/10.1038/s41598-017-00482-4] [PMID: 28352114]

Atobe, M.; Serizawa, T.; Yamakawa, N.; Takaba, K.; Nagano, Y.; Yamaura, T.; Tanaka, E.; Tazumi, A.; Bito, S.; Ishiguro, M.; Kawanishi, M. Discovery of 4,6- and 5,7-disubstituted isoquinoline derivatives as a novel class of protein kinase C ζ inhibitors with fragment-merging strategy. J. Med. Chem., 2020, 63(13), 7143-7162.
[http://dx.doi.org/10.1021/acs.jmedchem.0c00449] [PMID: 32551607]

Kaur, M.; Singh, M.; Silakari, O. Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: Designing, synthesis and biological evaluation. Future Med. Chem., 2017, 9(11), 1193-1211.
[http://dx.doi.org/10.4155/fmc-2017-0037] [PMID: 28722479]

Watterson, S.H.; Liu, Q.; Beaudoin Bertrand, M.; Batt, D.G.; Li, L.; Pattoli, M.A.; Skala, S.; Cheng, L.; Obermeier, M.T.; Moore, R.; Yang, Z.; Vickery, R.; Elzinga, P.A.; Discenza, L.; D’Arienzo, C.; Gillooly, K.M.; Taylor, T.L.; Pulicicchio, C.; Zhang, Y.; Heimrich, E.; McIntyre, K.W.; Ruan, Q.; Westhouse, R.A.; Catlett, I.M.; Zheng, N.; Chaudhry, C.; Dai, J.; Galella, M.A.; Tebben, A.J.; Pokross, M.; Li, J.; Zhao, R.; Smith, D.; Rampulla, R.; Allentoff, A.; Wallace, M.A.; Mathur, A.; Salter-Cid, L.; Macor, J.E.; Carter, P.H.; Fura, A.; Burke, J.R.; Tino, J.A. Discovery of branebrutinib (BMS-986195): A strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of bruton’s tyrosine kinase (BTK). J. Med. Chem., 2019, 62(7), 3228-3250.
[http://dx.doi.org/10.1021/acs.jmedchem.9b00167] [PMID: 30893553]

Bua, S.; Di Cesare Mannelli, L.; Vullo, D.; Ghelardini, C.; Bartolucci, G.; Scozzafava, A.; Supuran, C.T.; Carta, F. Design and synthesis of novel nonsteroidal anti-inflammatory drugs and carbonic anhydrase inhibitors hybrids (NSAIDs–CAIs) for the treatment of rheumatoid arthritis. J. Med. Chem., 2017, 60(3), 1159-1170.
[http://dx.doi.org/10.1021/acs.jmedchem.6b01607] [PMID: 28075587]

Shi, L.; Zhong, Z.; Li, X.; Zhou, Y.; Pan, Z. Discovery of an orally available janus kinase 3 selective covalent inhibitor. J. Med. Chem., 2019, 62(2), 1054-1066.
[http://dx.doi.org/10.1021/acs.jmedchem.8b01823] [PMID: 30615446]

Nosengo, N. Can you teach old drugs new tricks? Nature, 2016, 534(7607), 314-316.
[http://dx.doi.org/10.1038/534314a] [PMID: 27306171]

Kantarjian, H.M.; Prat, F.; Steensma, D.P.; Kurzrock, R.; Stewart, D.J.; Sekeres, M.A.; Leveque, J. Cancer research in the United States: A critical review of current status and proposal for alternative models. Cancer, 2018, 124(14), 2881-2889.
[http://dx.doi.org/10.1002/cncr.31522] [PMID: 29757456]

Moore, T.J.; Zhang, H.; Anderson, G.; Alexander, G.C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US food and drug administration, 2015-2016. JAMA Intern. Med., 2018, 178(11), 1451-1457.
[http://dx.doi.org/10.1001/jamainternmed.2018.3931] [PMID: 30264133]

Martin, L.; Hutchens, M.; Hawkins, C.; Radnov, A. How much do clinical trials cost? Nat. Rev. Drug Discov., 2017, 16(6), 381-382.
[http://dx.doi.org/10.1038/nrd.2017.70] [PMID: 28529317]

Yang, X.; Wang, Y.; Byrne, R.; Schneider, G.; Yang, S. Concepts of artificial intelligence for computer-assisted drug discovery. Chem. Rev., 2019, 119(18), 10520-10594.
[http://dx.doi.org/10.1021/acs.chemrev.8b00728] [PMID: 31294972]

Esteva, A.; Kuprel, B.; Novoa, R.A.; Ko, J.; Swetter, S.M.; Blau, H.M.; Thrun, S. Dermatologist-level classification of skin cancer with deep neural networks. Nature, 2017, 542(7639), 115-118.
[http://dx.doi.org/10.1038/nature21056] [PMID: 28117445]

Gulshan, V.; Peng, L.; Coram, M.; Stumpe, M.C.; Wu, D.; Narayanaswamy, A.; Venugopalan, S.; Widner, K.; Madams, T.; Cuadros, J.; Kim, R.; Raman, R.; Nelson, P.C.; Mega, J.L.; Webster, D.R. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA, 2016, 316(22), 2402-2410.
[http://dx.doi.org/10.1001/jama.2016.17216] [PMID: 27898976]

Stoel, B. Use of artificial intelligence in imaging in rheumatology - current status and future perspectives. RMD Open, 2020, 6(1), e001063.
[http://dx.doi.org/10.1136/rmdopen-2019-001063] [PMID: 31958283]